18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

October 6, 2022

Study Completion Date

October 6, 2022

Conditions
Pancreatitis, GraftPancreatic Transplant Post-Transplant Dysfunction Rejection
Interventions
DRUG

18F-fluciclovine

18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.

Trial Locations (1)

84132

University of Utah Hospital, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT04852523 - 18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants | Biotech Hunter | Biotech Hunter